http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2384399-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6d6b0a9721d7b7ca7d5f368df0f3658 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2007-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1462118d0e07f558a17c21dc52344ea4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66396eab83168cb9f27384af79e66d8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03ed4081e3009ccbc49fffe30b322408 |
| publicationDate | 2012-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2384399-T3 |
| titleOfInvention | Combination of interferon beta and a cladribine regimen to treat multiple sclerosis |
| abstract | The use of a combination of cladribine and interferon beta for the manufacture of a medicament to treat patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis, where cladribine should be administered orally following the following Sequential steps: (i) an induction period where cladribine is administered and in which the total dose of cladribine reached at the end of the induction period is approximately 1.7 mg / kg to approximately 3.5 mg / kg; (ii ) a period without cladribine in which cladribine is not administered; (iii) a maintenance period in which cladribine is administered and where the total dose of cladribine administered during the maintenance period is less than or equal to the total dose of cladribine reached at the end of the induction period (i); (iv) a period without cladribine in which cladribine is not administered. |
| priorityDate | 2006-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.